We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mural Oncology PLC | NASDAQ:MURA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 0.90% | 3.38 | 3.31 | 3.48 | 3.48 | 3.33 | 3.39 | 132,285 | 01:00:00 |
Interleukin-18 engineered for resistance to IL-18 binding protein (IL-18BP) and half-life extension to enhance its therapeutic potential (Abstract #4076):
“Resistance to IL-18BP is the foundation of our approach. The mutations we introduced prevented the binding protein from neutralizing the cytokine’s efficacy. We show that resistance to IL-18BP combined with the drug’s extended half-life leads to a durable immunological effect in preclinical models. Our observation of increases in Th1 cytokines, which have been shown elsewhere to correlate with response to checkpoint inhibitors, are encouraging indications that our engineered IL-18 may provide a therapeutic complement to checkpoint inhibitor immunotherapy1,2,” said Mark Whitmore, Ph.D., Principal Scientist of Cancer Biology, and the poster’s lead author.
Generation of tumor targeted self-assembling split IL-12 subunits for the treatment of cancer (Abstract #4066):
“We believe that by self-assembling the split IL-12 subunits within the tumor microenvironments, we can circumvent native IL-12’s severe toxicities without compromising its efficacy. The data presented today provide strong rationale for our strategy of non-competitively targeting each subunit to a unique epitope on the same molecule,” said Joshua Heiber, Ph.D., Director of Research & Development, Cancer Biology, and the poster’s lead author.
About Mural OncologyMural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin alfa (nemvaleukin), is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer, and we expect to nominate IL-18 and IL-12 candidates later this year. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company’s pipeline and development programs, including the expected timing of candidate selection, preclinical data, the potential of the Company’s programs to address unmet medical needs, and the continued progress of its pipeline and programs. Any forward-looking statements in this statement are based on the Company’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, the inherent risks and uncertainties associated with competitive developments, preclinical development, clinical trials, product development activities and regulatory approval requirements; that preclinical results, including the data from preclinical studies of the Company’s IL-18 and IL-12 programs referred to in this release, may not be predictive of results of future clinical studies or real-world results; and those other risks and uncertainties set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent filings the Company may make with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
1 Ayers et al. (2017) Journal of Clinical Investigation 127(8): 2930-2940.2 Karachaliou et al. (2018) Therapeutic Advances in Medical Oncology 10: 1-23.
Contacts
Investors:David Borah, CFAdavid.borah@muraloncology.com
Media:Katie Sullivankatie.sullivan@muraloncology.com
1 Year Mural Oncology Chart |
1 Month Mural Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions